Drug discovery

PCOM, The Wistar Institute Announce Cancer Biology Graduate Program

Retrieved on: 
Wednesday, March 20, 2024
Wistar Institute, Drug discovery, Patient, PCOM, Research, News, Cancer, Doctor of Philosophy, Faculty, Student, Drug development, Biomedical sciences, School

Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.

Key Points: 
  • Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.
  • , Wistar President and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor.
  • The Cancer Biology Graduate Program—jointly administered by Wistar and PCOM—will train individuals for a successful academic or industrial career in cancer biology and drug development.
  • At the conclusion of their studies, successful candidates will be granted a Ph.D. in cancer biology from PCOM.

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Retrieved on: 
Wednesday, March 20, 2024
Cancer, Drug discovery, Patient, SAN, Inflammation, Poster, Biochemistry, Clinical trial, Therapy, Paclitaxel, Safety, ACS, American Chemical Society, Lymphoma, Pharmaceutical industry

SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA. This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.

Key Points: 
  • This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.
  • “Today’s presentation at the ACS meeting showcases Nurix’s innovative combination of structure-based-drug-design and industry-leading expertise in the biochemistry of E3 ligases,” noted Gwenn Hansen, Ph.D., Nurix’s chief scientific officer.
  • This mechanism of action is notable because CBL-B lacks a classic enzymatic active site binding pocket, preventing typical inhibitor design and thereby requiring a novel drug discovery approach.
  • A copy of the presentation is available on the Posters and Presentations section of the scientific resources page of Nurix’s website.

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Retrieved on: 
Wednesday, March 20, 2024
Medicines Discovery Catapult, Francis Crick Institute, AstraZeneca, Science, Drug discovery, Novartis, Fraunhofer, Patient, IPA, University, GE HealthCare, Biophysics, Fundamental, Investment, Pharmaceutical industry

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Key Points: 
  • Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
  • Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.
  • Keno Gutierrez, Chairman of the Board of FundaMental Pharma, commented: “We are excited to share that Lorenz, a seasoned and highly regarded industry leader, has joined our Board of Directors.
  • I am confident that Lorenz`s energy, conceptual guidance and reach will make a difference in advancing FundaMental Pharma`s key program to the next level.”

Impressive $3.3M investment in Basic Mental Health Research

Retrieved on: 
Tuesday, March 19, 2024
Depression, Health, Basics, Mental health, Obesity, Prevalence, Drug discovery, University of Calgary, Insulin, Risk, Knowledge, Insulin resistance, The Honourable, Power Corporation of Canada, Research, Anxiety, University, Laboratory, Health Canada, Woman, Addiction, University of Toronto, Nursing

Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.

Key Points: 
  • Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.
  • The Basics of Better Mental Health Program funds basic research that will provide insight into the causes and onset of mental health conditions, explore the neuropathological changes and information-processing deficits that may eventually lead to new directions for treatments and interventions, and explore the role of sex and gender in mental health.
  • "Brain research plays a critical role in increasing our understanding of the causes and onset of mental health conditions,” says the Honourable Ya’ara Saks, Minister of Mental Health and Addictions.
  • “I am thrilled to support the work being done through the Basics of Better Mental Health Program – this work will support better mental health for all Canadians.”
    “The inclusion of sex-specific biological considerations is instrumental in understanding the biological roots of mental health conditions,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Retrieved on: 
Tuesday, March 19, 2024
COCP, Drug discovery, Patient, Lung, IND, Influenza A virus, Safety, FDA, Feedback, Food, Vaccine

BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A. A Pre-IND review provides the opportunity to obtain FDA guidance and clarification on critical steps such as the proposed clinical trial design, as well as clinical drug manufacturing and nonclinical studies deemed necessary before filing the trial design. The feedback was provided in a written response to a Pre-IND package and questions submitted by the Company in January 2024.

Key Points: 
  • The feedback was provided in a written response to a Pre-IND package and questions submitted by the Company in January 2024.
  • The Company expects to report topline results from this study in the second half of this year.
  • In addition, oral CC-42344 demonstrated favorable safety and tolerability results in a Phase 1 study in Australia.
  • This antiviral candidate was discovered using the Company’s proprietary structure-based drug discovery platform technology.

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Tuesday, March 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

NVIDIA Launches Generative AI Microservices for Developers to Create and Deploy Generative AI Copilots Across NVIDIA CUDA GPU Installed Base

Retrieved on: 
Monday, March 18, 2024
Cloud, Hewlett Packard Enterprise, Azure, GTC, Google Cloud, Ecosystem, Box, Running, Personal computer, Weight, Catalog, Adobe, Abridge, San Jose Convention Center, Cohere, Microsoft, Speech, SAN, Oracle Cloud, AWS, CrowdStrike, Language, NetApp, Snowflake, HP, Weather, Drug discovery, Library, RAG, Getty Images, SAP, AI, Mistral, Amazon Web Services, Dell Technologies, API, Dropbox, Data, HPE, Stable Diffusion, Stability, ServiceNow, CUDA, Meta, HPC, Supermicro, RIVA, Graphics processing unit, MLOps, NIM, OpenShift

Built on top of the NVIDIA CUDA ® platform, the catalog of cloud-native microservices includes NVIDIA NIM ™ microservices for optimized inference on more than two dozen popular AI models from NVIDIA and its partner ecosystem.

Key Points: 
  • Built on top of the NVIDIA CUDA ® platform, the catalog of cloud-native microservices includes NVIDIA NIM ™ microservices for optimized inference on more than two dozen popular AI models from NVIDIA and its partner ecosystem.
  • Among the first to access the new NVIDIA generative AI microservices available in NVIDIA AI Enterprise 5.0 are leading application, data and cybersecurity platform providers including Adobe , Cadence , CrowdStrike , Getty Images, SAP , ServiceNow , and Shutterstock.
  • NVIDIA AI Enterprise microservices are coming to infrastructure software platforms including VMware Private AI Foundation with NVIDIA.
  • Enterprises can deploy production-grade NIM microservices with NVIDIA AI Enterprise 5.0 running on NVIDIA-Certified Systems and leading cloud platforms.

NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health

Retrieved on: 
Monday, March 18, 2024
Nexus, Cloud, Hewlett Packard Enterprise, Azure, GTC, Google Cloud, Health, Metropolis, Patient, History, Orion, LLM, Therapy, San Jose Convention Center, Microsoft, Synthetic media, Vanilla, SAN, Oracle Cloud, 3D, AUC, Protein folding, AWS, Chemistry, Hippocrates, Flywheel, Amgen, Data management, Drug discovery, Acceleration, Hospital, Cadence, AI, Medtech, Dell Technologies, Amazon Web Services, API, CPU, VISTA, Supermicro, Biology, NIM, Universal, Collection, NVIDIA, Generative, Medical device

The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.

Key Points: 
  • The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.
  • These include screening for trillions of drug compounds to advance medicine, gathering better patient data to aid early disease detection and implementing smarter digital assistants.
  • “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”
    The new suite of healthcare microservices includes NVIDIA NIM , which provides optimized inference for a growing collection of models across imaging, medtech, drug discovery and digital health.
  • Hippocratic AI is developing task-specific Generative AI Healthcare Agents, powered by the company’s safety-focused LLM for healthcare, connected to NVIDIA Avatar Cloud Engine microservices and will utilize NVIDIA NIM for low-latency inferencing and speech recognition.

Sino Biological Announces Services Partnership with Rapid Novor

Retrieved on: 
Thursday, March 14, 2024
ChiNext, Drug discovery, Partnership, Research, Protein, Antibody, De novo, Vaccine

BEIJING, China, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc. (“Rapid Novor”).  Under the terms of this agreement, Sino Biological will market Rapid Novor’s proprietary de novo REmAb monoclonal antibody (mAb) sequencing service in combination with its custom mAb development and production services.  Geographic areas covered under this partnership include China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Japan and South Korea.

Key Points: 
  • BEIJING, China, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services , is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc. (“Rapid Novor”).
  • Under the terms of this agreement, Sino Biological will market Rapid Novor’s proprietary de novo REmAb monoclonal antibody (mAb) sequencing service in combination with its custom mAb development and production services.
  • Headquartered in Beijing, China, Sino Biological is the world’s leading provider of mammalian cell-based recombinant proteins, antibodies, and related contract research services.
  • Rob Burgess, Sino Biological’s Chief Business Officer, stated, “Rapid Novor’s REmAb monoclonal antibody sequencing capabilities perfectly complement Sino Biological’s antibody development and manufacturing services.

Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Health, Longevity, Drug discovery, Science, Media, Partnership, Education, Patient, Research, Security (finance), Investigational New Drug, OTC, Catalog, Immune system, International Cannabinoid Research Society, Nursing, Pharmaceutical industry

Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.

Key Points: 
  • Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.
  • In Australia, there are natural extracts that demonstrate outstanding potential in the medical and health field.
  • GenBio has reviewed numerous natural extracts over the last five years.
  • GenBio’s current research program is a potentially powerful anti-inflammatory drug program with lower toxicity than existing pharmaceutical drugs.